RxDoctor Payments Data

Otis Ferguson, MD

Ophthalmology · Detroit, MINPI 1215013297

Payments from drug & device makers

$1,102in general payments, 2019–2025

Across 36 payments — averaging $30.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$265
  • Oyster Point Pharma, Inc.$236
  • Carl Zeiss Meditec USA, Inc.$159
  • NEW World Medical,inc.$132
  • Teva Pharmaceuticals USA, Inc.$122
  • Sun Pharmaceutical Industries Inc.$42
  • plus $146 from 6 others

What the payments were for

  • Food & beverage$1,102100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,102 in reported general payments places this provider in the 45th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$89,419
Medicare patients
297
Services billed
1,021

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost133$49,364
RocklatanNetarsudil Mesylat/Latanoprost37$12,874
RestasisCyclosporine15$11,858
Cyclosporine28$11,134
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol67$9,059
CombiganBrimonidine Tartrate/Timolol36$6,876
Travoprost28$6,499
SimbrinzaBrinzolamide/Brimonidine Tart31$5,947
ZyletTobramycin/Lotepred Etab14$4,473
Brimonidine Tartrate51$4,437
Prednisolone Acetate137$4,267
Alphagan PBrimonidine Tartrate19$4,234
Latanoprost239$3,947
Brinzolamide11$3,746
Loteprednol Etabonate15$3,113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$265$72,332203 claims
Aerie Pharmaceuticals, Inc.Rocklatan$35$12,87437 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCZylet, Loteprednol Etabonate$24$7,58729 claims
AlconSimbrinza$35$5,94731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →